Study wrapper · #542
Growth hormone releasing peptide-6 (GHRP-6) ameliorates acute lung injury and its subsequent evolvement to interstitial fibrosis.
Editor's note
This is a preclinical mouse study — described by the authors as the first assessment of GHRP-6 in lung injury — testing the peptide in LPS- and zymosan/PAF-induced acute lung injury and its progression to fibrosis, across acute and chronic time points. Researchers reported that in the acute setting GHRP-6 was associated with reduced neutrophilic alveolitis, better lung compliance, improved alveolar-capillary permeability, and lower IL-1beta, and in the chronic setting with preserved lung structure and less collagen accumulation. These are early preclinical findings in a first-in-area rodent study; human data are needed before clinical conclusions can be drawn. The work opens a new research direction for GHRP-6 rather than establishing any clinical role, and effect sizes and dosing remain to be characterized.
Plain-language abstract
This mouse study asked whether GHRP-6, a small growth-hormone-releasing peptide, could reduce lung damage — the kind seen in acute respiratory distress, which can later turn into lung scarring. Researchers triggered lung injury using bacterial toxin (LPS) or a combination of zymosan and a platelet-activating factor, then gave GHRP-6 at various doses and followed the animals for either a short or long period. In the short term, GHRP-6 was associated with less inflammatory-cell flooding of the air sacs, better lung mechanics, less leaky lung blood vessels, and lower levels of an inflammatory signal (IL-1beta). Over the longer term, treated lungs kept more of their normal structure and built up less scar tissue. The authors call this the first look at GHRP-6 for lung injury. Because it is an animal study, the results describe mouse biology and cannot be applied directly to people.